Kinetic analysis of a monoclonal therapeutic antibody and its single-chain homolog by surface plasmon resonance

Analytical Biochemistry

Volumn 396, Issue 1, 2010, Pages 59-68

  Patel, Rekha ^a   Andrien Jr , Bruce A ^a  

^a ALEXION PHARMACEUTICALS   (United States)

Author keywords

Biacore; Kinetics; Monoclonal antibodies; scFv; Thermodynamics

Indexed keywords

ASSOCIATION REACTIONS; BINDING ENERGY; ENZYME KINETICS; EPITOPES; KINETICS; MONOCLONAL ANTIBODIES; PLASMONS; THERMODYNAMICS;

BIACORE; BINDING CHARACTERISTICS; FUNCTIONAL CHARACTERIZATION; MONOCLONAL ANTIBODIES (MABS); SCFV; SINGLE CHAIN VARIABLE FRAGMENTS; SINGLE-CHAIN ANTIBODIES; STRUCTURAL CHARACTERIZATION;

SURFACE PLASMON RESONANCE;

MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BIOTECHNOLOGY; CONTROLLED STUDY; EPITOPE MAPPING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; SURFACE PLASMON RESONANCE; THERMODYNAMICS;

EID: 70449635150     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.08.034     Document Type: Article

References (42)

1. Stockwin L.H., and Holmes S. The role of therapeutic antibodies in drug discovery. Biochem. Soc. Trans. 31 (2003) 433-436
2. Piggee C. Therapeutic antibodies coming through the pipeline. Anal. Chem. 80 (2008) 2305-2310
3. Nissim A., and Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handbook of Experimental Pharmacology vol. 181 (2008), Springer, Berlin 3-18
4. Zhang Q., Chen G., Liu X., and Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res. 17 (2007) 89-99
5. Hudson P.J., and Souriau C. Engineered antibodies. Nat. Med. 9 (2003) 129-134
6. Paul C. Improving the efficacy of antibody-based cancer therapies. Nature 1 (2001) 118-129
7. Chowdhury P.S., and Wu H. Tailor-made antibody therapeutics. Methods 36 (2005) 11-21
8. Reichert J.M., Rosenweig C.J., Faden L.B., and Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23 (2005) 1073-1078
9. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715
10. Scott C.T. The problem with potency. Nat. Biotechnol. 23 (2005) 1037-1039
11. Gallen C.C. Strategic challenges in neurotherapeutic pharmaceutical development. NeuroRx 1 (2004) 165-180
12. Reichert J.M. Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. 2 (2003) 695-702
13. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
14. Elrick L.J., Leel V., Blaylock M.G., Duncan L., Drever M.R., Strachan G., Charlton K.A., Koruth M., Porter A.J., and Wright M.C. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells: a potential mechanism for targeting liver anti-fibrotic therapeutics. J. Hepatol. 42 (2005) 888-896
15. Danielyan K., Ding B.-S., Gottstein C., Cines D.B., and Muzykantov V.R. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J. Pharmacol. Exp. Ther. 321 (2007) 947-952
16. Li S.L., Liang S.J., Guo N., Wu A.M., and Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor 1 receptor: expression, purification, and effect on tumour growth. Cancer Immunol. Immunother. 49 (2000) 243-252
17. Backmann N., Zahnd C., Huber F., Bietsch A., Plückthun A., Lang H.-P., Güntherodt H.-J., Hegner M., and Gerber C. A label-free immunosensor array using single-chain antibody fragments. Proc. Natl. Acad. Sci. USA 102 (2005) 14587-14592
18. Hooks M.A., Wade C.S., and Millikan W.J. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11 (1991) 26-37
19. Reichert J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9 (2008) 423-430
20. Orita T., Tsunoda H., Yabuta N., Nakano K., Yoshino T., Hirata Y., Ohtomo T., Nezu J., Sakumoto H., Ono K., Saito M., Kumagai E., Nanami M., Kaneko A., Yoshikubo T., and Tsuchiya M. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 105 (2005) 562-566
21. Mabry R., Rani M., Geiger R., Hubbard G.B., Carrion Jr. R., Brasky K., Patterson J.L., Georgiou G., and Iverson B.L. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect. Immun. 73 (2005) 8362-8368
22. Karlsson R., and Fält A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J. Immunol. Methods 200 (1997) 121-133
23. Myszka D.G. Kinetic, equilibrium, and thermodynamic analysis of macromolecular interactions with Biacore. Methods Enzymol. 323 (2000) 325-340
24. Myszka D.G., He X., Dembo M., Morton T.A., and Goldstein B. Extending the range of rate constants available from Biacore: interpreting mass transport-influenced binding data. Biophys. J. 75 (1998) 583-594
25. Yu H., Muñoz E.M., Edens R.E., and Lindhardt R.J. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim. Biophys. Acta 1726 (2005) 168-176
26. Kim D.R. Determination of monoclonal antibodies capable of recognizing the native protein using surface plasmon resonance. J. Biochem. Mol. Biol. 34 (2001) 452-456
27. Johne B., Gadnell M., and Hansen K. Epitope mapping and binding kinetics of monoclonal antibodies studied by real-time biospecific interaction analysis using surface plasmon resonance. J. Immunol. Methods 160 (1993) 191-198
28. Van Regenmortel M.H.V., Altschuh D., Chatellier J., Christensen L., Rauffer-Bruyére N., Richalet-Secordel P., Witz J., and Zeder-Lutz G. Measurement of antigen-antibody interactions with biosensors. J. Mol. Recognit. 11 (1998) 163-167
29. Ashish B., and Murthy G.S. Analysis of human chorionic gonadotropin-monoclonal antibody interaction in Biacore. J. Biosci. 29 (2004) 57-66
30. Rich R.L., Papalia G.A., Flynn P.J., Fumeisen J., Quinn J., Klein J.S., et al. A global benchmark study using affinity-based receptors. Anal. Biochem. 386 (2009) 194-216
31. Zeder-Lutz G., Zuber E., Witz J., and Van Regenmortel M.H. Thermodynamic analysis of antigen-antibody binding using biosensor measurements at different temperatures. Anal. Biochem. 246 (1997) 123-132
32. Bongini L., Fanelli D., Piazza F., De Los Rios P., Sanner M., and Skoglund U. A dynamical study of antibody-antigen encounter reactions. Phys. Biol. 4 (2007) 172-180
33. Mukkur T.K. Thermodynamics of hapten-antibody interactions. CRC Crit. Rev. Biochem. 16 (1984) 133-167
34. Altobelli G., and Subramanium S. Kinetics of association of anti-lysozyme monoclonal antibody D44.1 and hen-egg lysozyme. Biophys. J. 79 (2000) 2954-2965
35. Edwards D. Steric hindrance effects on surface reactions: applications to Biacore. J. Math. Biol. 55 (2007) 517-539
36. Vijayendran R.A., and Leckband D.E. A quantitative assessment of heterogeneity for surface-immobilized proteins. Anal. Chem. 73 (2001) 471-480
37. Robbio L.L., Uboldi P., Marcovina S., Revoltella R.P., and Catapano A.L. Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor. Biosens. Bioelectron. 16 (2001) 963-969
38. Rosenberg A.S. Effects of protein aggregates: an immunologic perspective. AAPS J. 8 (2006) E501-E507
39. Schellenkens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24 (2002) 1720-1740
40. Moore J.M., Patapoff T.W., and Cromwell M.E. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38 (1999) 13960-13967
41. Canziani G.A., Klakamp S., and Myszka D.G. Kinetic screening of antibodies from crude hybridoma samples using Biacore. Anal. Biochem. 325 (2004) 301-307
42. Myszka D.G. Improving biosensor analysis. J. Mol. Recognit. 12 (1999) 279-284